Angiogenesis is an essential step for many physiological and pathological processes. Tumor necrosis factor (TNF) superfamily cytokines are increasingly recognized as key modulators of angiogenesis. In this study, we tested whether TNF-related activation-induced cytokine (TRANCE), a new member of the TNF superfamily, possesses angiogenic activity in vitro and in vivo. TRANCE stimulated DNA synthesis, chemotactic motility, and capillary-like tube formation in primary cultured human umbilical vein endothelial cells (HUVECs). Both Matrigel plug assay in mice and chick chorioallantoic membrane assay revealed that TRANCE potently induced neovascularization in vivo. TRANCE had no effect on vascular endothelial growth factor (VEGF) expression in HUVECs and TRANCE-induced angiogenic activity was not suppressed by VEGF-neutralizing antibody, implying that TRANCE-induced angiogenesis may be the result of its direct action on endothelial cells. TRANCE evoked a time-and dose-dependent activation of the mitogen-activated protein kinases ERK1/2 and focal adhesion kinase p125 FAK in HUVECs, which are closely linked to angiogenesis. These signaling events were blocked by the Src inhibitor PP1 or the phospholipase C (PLC) inhibitor U73122. Furthermore, these inhibitors and the Ca 2؉ chelator BAPTA-AM suppressed TRANCE-induced HUVEC migration. These results indicate that the angiogenic activity of TRANCE is mediated through the Src-PLC-Ca 2؉ signaling cascade upon receptor engagement in endothelial cells, suggesting the role of TRANCE in neovessel formation under physiological and pathological conditions.
Angiogenesis is an essential step for many physiological and pathological processes. Tumor necrosis factor (TNF) superfamily cytokines are increasingly recognized as key modulators of angiogenesis. In this study, we tested whether TNF-related activation-induced cytokine (TRANCE), a new member of the TNF superfamily, possesses angiogenic activity in vitro and in vivo. TRANCE stimulated DNA synthesis, chemotactic motility, and capillary-like tube formation in primary cultured human umbilical vein endothelial cells (HUVECs). Both Matrigel plug assay in mice and chick chorioallantoic membrane assay revealed that TRANCE potently induced neovascularization in vivo. TRANCE had no effect on vascular endothelial growth factor (VEGF) expression in HUVECs and TRANCE-induced angiogenic activity was not suppressed by VEGF-neutralizing antibody, implying that TRANCE-induced angiogenesis may be the result of its direct action on endothelial cells. TRANCE evoked a time-and dose-dependent activation of the mitogen-activated protein kinases ERK1/2 and focal adhesion kinase p125 FAK in HUVECs, which are closely linked to angiogenesis. These signaling events were blocked by the Src inhibitor PP1 or the phospholipase C (PLC) inhibitor U73122. Furthermore, these inhibitors and the Ca 2؉ chelator BAPTA-AM suppressed TRANCE-induced HUVEC migration. These results indicate that the angiogenic activity of TRANCE is mediated through the Src-PLC-Ca 2؉ signaling cascade upon receptor engagement in endothelial cells, suggesting the role of TRANCE in neovessel formation under physiological and pathological conditions. Angiogenesis, the formation of new blood vessels from preexisting endothelium, is a fundamental step in a variety of physiological and pathological conditions including wound healing, embryonic development, chronic inflammation, and tumor growth (1) (2) (3) . The angiogenic process is tightly controlled by a wide variety of positive or negative regulators, which are composed of growth factors, cytokines, lipid metabolites, and cryptic fragments of hemostatic proteins (4) , and many of these factors are initially characterized in other biological activities. Positive regulators of angiogenesis are classified into two groups: direct inducers, such as vascular endothelial growth factor (VEGF) 1 and bFGF that can induce proliferation, migration, and morphogenesis of endothelial cells and indirect inducers that act on endothelial cells via production of direct angiogenic factors from accessory cells such as immune cells and tumor cells (4) .
Tumor necrosis factor (TNF)-related activation-induced cytokine (TRANCE), also called ODF, RANKL, and OPGL, is a novel member of the TNF family ligands that regulates immune responses and bone remodeling (5) (6) (7) (8) . TRANCE expressed on activated T cells promotes the survival of dendritic cells and modulates T helper cell responses to viral infections (9, 10) . TRANCE is also highly expressed on osteoblasts and plays a key role in osteoclast differentiation from hematopoietic precursors and calcium metabolism (11, 12) . Recently, it has been also reported that, in a T cell-dependent model of rat adjuvant arthritis, TRANCE regulates bone loss and cartilage destruction (13) . These effects of TRANCE are exerted by its binding to the transmembrane receptor RANK (receptor activator of NF-B). RANK is detected on mature dendritic cells, chondrocytes, osteoclast precursors, and mature osteoclasts (9, 14) and induces activation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), AKT, and NF-B in dendritic cells and osteoclasts (15) (16) (17) .
The vasculature is crucial for the processes of bone formation by paving the way for a variety of cells essential for bone morphogenesis, including osteoblasts, to migrate into cartilage (18, 19) . Osteoblasts express TRANCE, which can interact with RANK on the surface of endothelial cells during migration into cartilage. Thus, we postulated the possibility that TRANCE may contribute to the proper formation of new blood vessels. We here provide several lines of evidence that TRANCE potently induces angiogenesis in vivo and directly activates proliferation, migration, and morphogenesis of endothelial cells.
MATERIALS AND METHODS
Reagents and Chemicals-Soluble TRANCE (hCD8-conjugated form) was purified from insect cells as described previously (15) . bFGF and VEGF were from Upstate Biotechnology (Lake Placid, NY). U73122, U73343, PP1, GF109203X, and U0126 were from BIOMOL. Phorbol 12-myristate 13-acetate (PMA) were from Alexis (Laufelfingen, Switzerland). M199, heparin, and Trizol Reagent were purchased from Invitrogen (Grand Island, NY FAK was from Upstate Biotechnology. Anti-phosphotyrosine antibody was from Transduction Laboratories (Lexington, KY). Antibody for VEGF was from R&D Systems (Minneapolis, MN). All other reagents were purchased from Sigma unless indicated otherwise.
Cell Culture-Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord veins by collagenase treatment as described previously (20) and used in passages 2-7. The cells were grown in M199 medium supplemented with 20% fetal bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin, 3 ng/ml bFGF, and 5 units/ml heparin at 37°C within humidified 5% CO 2 /95% air.
Reverse Transcriptase (RT)-PCR Analysis-Total RNA was obtained from HUVECs using the Trizol Reagent kit. Five g of total RNA was converted to cDNA by treatment with 200 units of reverse transcriptase and 500 ng of oligo(dT) primer in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol and 1 mM dNTPs at 42°C for 1 h. The reaction was stopped by heating at 70°C for 15 min. 3 l of the cDNA mixture was used for enzymatic amplification. Polymerase chain reaction was performed in 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 , 0.2 mM dNTPs, 2.5 units of Taq DNA polymerase, and 0.1 M each of primers for RANK or VEGF. The reaction mixture was heated at 94°C for 1 min, annealed at 55°C for 2 min, and extended at 72°C for 3 min for 30 repetitive cycles. The primers used were 5Ј-CTCCAG-CGGGCAGGTGATGAACTT-3Ј (sense) and 5Ј-TCAAGCCTTGGCCCC-GCCTTGCTC-3Ј (antisense) for the RANK or 5Ј-GGCCTCCGAAACC-ATGAACTTTCTGCT-3Ј (sense) and 5Ј-CCTCCTGCCCGGCTCACCG-C-3Ј (antisense) for the VEGF. ␤-actin was used as an internal control.
In Vivo Matrigel Plug Assay-Matrigel plug assay was performed as previously described (21) . Briefly, C57/BL6 mice were injected subcutaneously with 0.5 ml of Matrigel containing the indicated amount of TRANCE with heparin (40 units/ml). The injected Matrigel rapidly formed a single, solid gel plug. After 5 days, mice were killed, and the Matrigel plugs were recovered, fixed with 3.7% formaldehyde/phosphate-buffered saline, and embedded in paraffin. The plugs were then sectioned and examined with Trichrome-Masson stain. The neovessel area was quantified using TINA 2.0 software (Fuji Inc.).
Chorioallantoic Membrane (CAM) Assay-Angiogenic assay with chick CAM was performed as previously described (22) . Fertilized chick embryos were preincubated for 9 days at 38°C with 70% humidity. A hole was drilled over the air sac at the end of the eggs, and an avascular zone was identified on the CAMs. A 1 ϫ 1-cm window in the shell was made to expose the CAM. Thermanox discs were sterilized and loaded with TRANCE (3 g/ml) and PMA (0.12 g/ml). After air-drying under the laminar flow, the discs were applied to the CAM surface of 9-day-old chick embryos. The windows were sealed with clear tape, and the eggs were incubated for 3 more days. Intrapos (Green-Cross) was injected under the upper CAM to increase contrast between vessels and background. Capillary formation was inspected using a light microscope.
[ 3 
H]Thymidine Incorporation Assay-[
3 H]Thymidine incorporation assay was performed as previously described (21) . Briefly, HUVECs were plated at a density of 2 ϫ 10 4 cells/well in a 24-well plate. Cells were incubated in growth media and allowed to attach for 24 h. Cells were washed twice with M199 and incubated for 6 h with M199 containing 1% FBS. Cells were stimulated by the addition of indicated concentration of TRANCE or 10 ng/ml VEGF for 30 h and followed by the addition of 1 Ci/ml H-labeled radioactivity was precipitated using 5% trichloroacetic acid at 4°C for 30 min.
After washing twice with ice-cold H 2 O, 3 H-labeled radioactivity was solubilized in 0.2 N NaOH containing 0.1% sodium dodecyl sulfate and determined by liquid scintillation counter.
Chemotaxis Assay-Chemotaxis assay was performed as previously described (21) . Briefly, the chemotactic motility of HUVECs was assayed using Transwell with 6.5-mm diameter polycarbonate filters (8-m pore size). The lower surface of the filter was coated with 10 g of gelatin. The fresh M199 media (1% FBS) containing TRANCE, bFGF, or VEGF were placed in the lower wells. HUVECs were trypsinized and suspended at a final concentration of 1 ϫ 10 6 cells/ml in M199 containing 1% FBS. Inhibitors were given to the cells for 30 min at room temperature before seeding. One hundred l of the cell suspension was loaded into each of the upper wells. The chamber was incubated at 37°C for 4 h. Cells were fixed and stained with hematoxylin and eosin. Nonmigrating cells on the upper surface of the filter were removed by wiping with a cotton swab, and chemotaxis was quantified by counting the cells that migrated to the lower side of the filter with optical microscope (ϫ200). Ten fields were counted for each assay.
Tube Formation Assay-Tube formation assay was performed as previously described (21) . Briefly, 250 l of growth factor-reduced Matrigel (10 mg protein/ml) was pipetted into a 16-mm diameter tissue culture well and polymerized for 30 min at 37°C. HUVECs incubated in M199 containing 1% FBS for 6 h were harvested after trypsin treatment, resuspended in M199, plated onto the layer of Matrigel at a density of 1 ϫ 10 5 or 4 ϫ 10 5 cells/well, and followed by the addition of 3 g/ml TRANCE. Matrigel cultures were incubated at 37°C. After 20 h, the cultures were photographed (ϫ40). The area covered by the tube network was determined using an optical imaging technique in which pictures of the tubes were scanned in Adobe Photoshop and quantitated using Image-Pro Plus (Media Cybernetics).
Measurement of Total Inositol Phosphate (IP T ) in HUVECs-
HUVECs were plated at a density of 2 ϫ 10 5 cells/well in six-well plates and allowed to recover for 24 h. The medium was then aspirated, and cells were incubated for 12 h in myo-inositol-free M199 media supplemented with [ 3 H]myo-inositol (1 Ci/ml, 25 mCi/mmol) (DuPont Biotechnology Systems) and 0.5% FBS. The cells were washed with phosphate-buffered saline and incubated in M199 media supplemented with 20 mM LiCl for 30 min, followed by additional incubation in the absence or presence of 0.5 g/ml TRANCE for 20 min. The incubation was terminated by adding perchloric acid to a final concentration of 5% (w/v). Cells were scraped into Eppendorf tubes and subjected to centrifugation. The supernatant was equilibrated with 2 M KOH/1 mM EDTA and was applied to SAX column. Bound inositol phosphates were eluted by the application of linear gradient (0.1 M ammonium phosphate) at a flow rate of 2 ml/min. The amount of radioactivity in the resulting fraction, corresponding to liberated [ 3 H]inositol triphosphate (IP 3 ), was measured by a liquid scintillation counter.
Immunoprecipitation-Confluent HUVECs were incubated for 6 h in M199 containing 1% FBS before addition of TRANCE. After stimulation, cells were lysed in 1 ml of lysis buffer containing 20 mM Tris/HCl, pH 8.0, 2 mM EDTA, 137 mM NaCl, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10% glycerol, and 1% Triton X-100. Lysates were clarified by centrifugation at 15,000 ϫ g for 10 min, and the resulting supernatants were immunoprecipitated with 1 g/ml of anti-FAK antibody for 3 h at 4°C, followed by the addition of protein A-agarose beads for 1 h at 4°C. Immunoprecipitates were washed three times with lysis buffer, solubilized in SDS-PAGE sample buffer, and further analyzed by Western blotting.
Western Blotting-Cell lysates or immunoprecipitates from HUVECs were electrophoresed on SDS-PAGE gel and transferred to polyvinyldifluoride membrane. The blocked membranes were then incubated with the indicated antibody, and the immunoreactive bands were visualized using chemiluminescent reagent as recommended by Amersham Biosciences, Inc.
Data Analysis and Statistics-The data are presented as means Ϯ S.E. or as percentages of control Ϯ S.E. from three different experiments with triplicate. Statistical comparisons between groups were performed using the Student's t test.
RESULTS
TRANCE Induces DNA Synthesis, Migration, and Tube Formation of HUVECs-The process of angiogenesis is complex and involves several discrete steps, including extracellular matrix degradation, proliferation, and migration of endothelial cells and morphological differentiation of endothelial cells to form tubes (4). To determine whether TRANCE induces angiogenesis, the ability of TRANCE as an angiogenic stimulus has been assessed in in vitro angiogenesis models. We have first examined the effect of TRANCE on HUVEC proliferation. TRANCE increased the total number of cells at 48 h following TRANCE treatment in a dose-dependent manner (Fig. 1A) . The effect of TRANCE on DNA synthesis of HUVECs was monitored by [ 3 H]thymidine incorporation assay (Fig. 1B) . TRANCE increased the DNA synthesis of HUVECs by 1.5-fold at 3 g/ml. The activity at 3 g/ml TRANCE was lower than that of VEGF at 10 ng/ml.
We next determined the effect of TRANCE on chemotactic motility of HUVECs by employing a modified Boyden chamber assay. TRANCE stimulated the chemotactic motility of HUVECs in a does-dependent manner with near maximal activity at 50 ng/ml (Fig. 1C) . The migratory activity at 50 ng/ml of TRANCE was 40% increase over the control, and the effect of TRANCE was comparable with those of the optimal concentration of bFGF (25 ng/ml) and VEGF (25 ng/ml), which are the known stimuli of HUVEC migration (Fig. 1D) .
The effect of TRANCE on the morphological differentiation of HUVECs was investigated using two-dimensional Matrigel. When placed on growth factor-reduced Matrigel in the absence of angiogenic factors, HUVECs formed incomplete and narrow tube-like structures ( Fig. 2A) . In contrast, the treatment of 3 g/ml TRANCE led to the formation of elongated and robust tube-like structures, which were organized by much larger number of cells compared with the control (Fig. 2A) . By measuring the area covered by the tube network using an image analysis program, TRANCE stimulated tube formation by 2-fold over the control (Fig. 2B) . We also observed that TRANCE induces tube formation of human microvascular endothelial cell line, HMEC-1 (data not shown). These results indicate that TRANCE has a novel angiogenic activity in in vitro human endothelial cell culture system. TRANCE Induces Angiogenesis in Vivo-To determine whether TRANCE is capable of promoting angiogenesis in vivo, experiments were first performed on the CAMs using Thermanox discs. After 72 h of contact with the CAM, the disc containing 3 g/ml TRANCE was associated with the significant induction of neovascularization (Fig. 3A) . The relative quantitation of the CAMs with a disc loaded with vehicle alone, a disc with PMA as a positive control, and a disc with 3 g/ml TRANCE are shown in Fig. 3B . The in vivo angiogenic activity of TRANCE was further evaluated by an established in vivo angiogenesis model, the mouse Matrigel plug assay. Matrigel with or without TRANCE (3 g/ml) was injected subcutaneously into C57/BL6 mice. The solid gel plug was removed from the mice at 5 days after implantation for histological examination. As shown in Fig. 3C , TRANCE produced more neovessels within gels than Matrigel alone. The vascular density and the number of mature vascular structures were significantly increased by TRANCE. When quantified by measurement of vascular areas in the fixed Matrigel plugs, the angiogenic activity of TRANCE was comparable with 50 ng/ml bFGF (data not shown). Taken together, these results indicate that TRANCE has a potent angiogenic activity in vivo.
TRANCE-induced Angiogenesis Does Not Require VEGF Expression in Endothelial Cells-The angiogenic activity of TRANCE may be the result of its direct action on endothelial cells or through the induction of other genes involved in angiogenesis (4). VEGF is a selective mitogen and motogen for endothelial cells. A number of angiogenic inducers including TNF␣, transforming growth factor-␤, interleukin-1␤, prostaglandins, and endothelins have been shown to induce expression of VEGF in various cell types, which is in part responsible for their role in angiogenesis (4) . We tested the possibility that the effect of TRANCE on angiogenesis is mediated through expression of VEGF.
The expression of VEGF by TRANCE in HUVECs was assessed by RT-PCR analysis. As previously reported, TNF␣ markedly increased the VEGF transcript in HUVECs, whereas TRANCE had no effect on the levels of VEGF mRNA (Fig. 4A) .
To confirm the results of RT-PCR analysis, we used a VEGFneutralizing antibody to test whether the angiogenic activities of TRANCE are mediated by VEGF. VEGF-neutralizing antibody significantly reduced VEGF-induced HUVEC proliferation, but had no effect on TRANCE-induced proliferation (Fig.  4B) . We also observed that TRANCE-induced HUVEC tube formation was not affected by VEGF-neutralizing antibody (data not shown). These results indicate that TRANCE-induced angiogenesis is not caused by the induction of VEGF expression, suggesting that TRANCE may act as a direct angiogenic modulator in endothelial cells. TRANCE and TNF␣ are classified as the same TNF superfamily ligand based on amino acid sequence homology and have fairly similar biological actions, mainly in immune response and the development of osteoclasts (6, 23). The present study showed that TRANCE also had an angiogenic activity in addition to TNF␣ as previously characterized. However, since TNF␣ has been shown to require VEGF expression for its angiogenic activity and have no direct action on endothelial cell proliferation and migration, the mechanism of the angiogenic action of TRANCE is likely to be distinct from that of TNF␣.
TRANCE Activates ERKs and p125
FAK in HUVECs-TRANCE induces intracellular signaling through the interaction with its receptor RANK. We confirmed the presence of RANK mRNA in HUVECs using RT-PCR analysis (Fig. 5A) . Immunoblot analysis showed expression of RANK protein in HUVECs, which is similar size to that reported in mouse dendritic cells (data not shown). To characterize the function of the TRANCE receptor in stimulating angiogenesis, we attempted to examine TRANCE-induced intracellular signals in endothelial cells. Recent studies have shown that activation of ERKs is closely involved in proliferation, migration, or morphogenesis of endothelial cells induced by various angiogenic factors. Therefore, we investigated whether TRANCE can stimulate ERKs in HUVECs. Subconfluent HUVECs were exposed to various concentrations of TRANCE, and the activation of ERK1/2 was analyzed by Western blot analysis using antibody directed against the phosphorylated form of ERK1/2 (p44 ERK1 and p42 ERK2). As shown in Fig. 5B , TRANCE induced ERK activation in a dose-and time-dependent manner, and maximal activation was observed after 20 min of TRANCE stimulation and declined thereafter. In contrast to the effect of TRANCE on ERK1/2, TNF␣ was not able to induce ERK activation in HUVECs (data not shown), suggesting that the intracellular signaling property of TRANCE is also distinct from that of TNF␣ in endothelial cells.
Focal adhesion kinase p125 FAK is believed to represent a primary signaling mediator for the dynamic changes in actin cytoskeleton reorganization that are a prerequisite for the promotion of cell migration (24, 25) . Recent work has shown that VEGF stimulates tyrosine phosphorylation of p125 FAK in HUVECs, and the resulting tyrosine phosphorylation is suggested to have a role in the migratory cell response to VEGF (26) . Thus, we next examined the effect of TRANCE on tyrosine   FIG. 3 . Identification of TRANCE-induced angiogenesis by mouse Matrigel plug assay and the chicken chorioallantoic membrane assay. Angiogenesis was induced by Themanox discs containing TRANCE (3 g/ml) or PMA (0.12 g/ml) on the CAM of 9-dayold chick embryos. The angiogenic response was assessed as positive after appearance of a significantly increased vascularization under or in the vicinity of the disc. A, the effect of TRANCE on the formation of new blood vessels in the CAMs. The representative areas of the CAM were pictured using a light microscope (ϫ16). Arrow indicates the formation of new blood vessels by TRANCE. B, comparison of the effect of TRANCE and PMA on the CAMs. Numerical values on the bars are expressed as the number of positive discs/total number of eggs. For the Matrigel plug assay, C57/BL6 mice were injected subcutaneously with 0.5 ml of Matrigel with or without TRANCE (3 g/ml). C, the effect of TRANCE on neovessel formation in the Matrigel (ϫ100). Arrow indicates the active neovessels containing red blood cells. D, quantitative effect of TRANCE on neovessel formation. Neovessel areas in the Matrigel plug were quantified using TINA 2.0 software. Four mice were used as a group, and the experiment was repeated twice.
FIG. 4. TRANCE does not induce VEGF expression.
A, the effect TRANCE on VEGF expression in HUVECs. HUVECs were cultured with 3 g/ml TRANCE or 50 ng/ml TNF␣. Total mRNAs were isolated, and RT-PCR was performed as described under "Material and Methods." B, the effect of VEGF-neutralizing antibody on TRANCE-induced DNA synthesis in HUVECs. HUVECs were stimulated with or without 3 g/ml TRANCE or 10 ng/ml VEGF in the presence or absence of 1 g/ml VEGF-neutralizing antibody and allowed to proliferate for 36 h. 
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phosphorylation of p125 FAK in HUVECs. We observed tyrosine phosphorylation of p125 FAK at 0.05 g/ml TRANCE (Fig. 5C ). The effective dose of TRANCE for p125 FAK activation was lower by one order than that for ERK activation, suggesting that p125
FAK is likely to be more sensitively triggered upon the TRANCE receptor engagement than ERKs. Kinetic analysis revealed phosphorylated p125 FAK to be detectable within 10 min after addition of TRANCE and declined to a basal level at 1 h (Fig. 5C ). Thus, this study demonstrates that, in addition to TRANCE-induced ERKs, NF-B, and AKT/PKB activation in other cells, TRANCE can activate p125 FAK in endothelial cells. This signaling event may provide support for a signaling cascade in which TRANCE induces cytoskeletal reorganizations resulting in cell spreading and migration.
TRANCE-induced ERKs and p125 FAK Activation in HUVECs Are Blocked by Inhibitors of Src Family Tyrosine
Kinases and PLC-To further delineate the TRANCEmediated signaling pathway in endothelial cells, we were prompted to explore the upstream signaling mechanisms related to activation of ERK and p125
FAK from receptor engagement. In dendritic cells and osteoclasts, the nonreceptor tyrosine kinase c-Src is shown to play a critical role in AKT/PKB activation by TRANCE (16) . We tested the involvement of Src family kinases on the TRANCE signaling pathway in HUVECs. Pretreatment of HUVECs with PP1, an inhibitor for Src family kinases, completely blocked both ERK and p125 FAK activation by TRANCE (Fig. 6) . These results indicate that Src family tyrosine kinases lie upstream of the ERK and p125 FAK cascades initiated by the TRANCE receptor in HUVECs. c-Src is previously shown to interact with RANK upon receptor engagement, and the resulting activation of c-Src is responsible for TRANCE-induced cell survival in dendritic cells (16) . Our data indicate that activation of Src is likely to be linked to TRANCEinduced angiogenic signaling pathway.
Since evidence has been presented that a Src family tyrosine kinase lies upstream of PLC-␥1 (27, 28) , we further examined the ability of PLC inhibitor to block TRANCE-induced ERK and p125 FAK activation. Pretreatment of HUVECs with the PLC inhibitor U73122 blocked TRANCE-induced ERK activation, while U73343, a structurally similar derivative of U73122 but inactive for PLC, had no effect (Fig. 6A) . U73122 also completely blocked TRANCE-induced p125 FAK phosphorylation (Fig. 6B) . PLC is known to generate IP 3 and diacylglycerol, which activate intracellular Ca 2ϩ mobilization and PKC, respectively. To confirm PLC activation, we measured the effect of TRANCE on IP 3 generation. As shown in Fig. 6C , treatment of HUVECs with 0.5 g/ml TRANCE for 20 min increased the cellular level of IP 3 by 1.6-fold over the control, providing evidence that TRANCE activates PLC in HUVECs. To further characterize the role of PLC in the TRANCE signaling pathway in HUVECs, we assessed the abilities of the intracellular Ca 2ϩ chelator BAPTA-AM and the PKC inhibitor GF109203X to block p125 FAK phosphorylation by TRANCE. BAPTA-AM completely inhibited TRANCE-induced p125 FAK phosphorylation (Fig. 6B) . In contrast to BAPTA-AM, GF109203X failed to exert a similar effect (Fig. 6B) . These data indicate that increased intracellular Ca 2ϩ by PLC activation is important for the TRANCE signaling pathway. Therefore, it is suggested that the Src-PLC␥1-Ca 2ϩ signaling cascade is most likely to be responsible for TRANCE-induced angiogenic signaling pathway.
Src Family Tyrosine Kinases and PLC Are Required for TRANCE-induced HUVEC Migration-The activation of ERK and p125
FAK pathway by TRANCE prompted us to determine whether these biochemical events are important for angiogenic activities of TRANCE. Thus, we tested the effects of inhibitors of ERK1/2, Src, and PLC on TRANCE-induced HUVEC chemotaxis. The endothelial ERK activity has been shown to modulate proliferation and morphogenesis of endothelial cells in several angiogenic factors (21, 29 -31) . In some cases this enzyme activity was also implicated in endothelial cell migration (31) . ERK is required for endothelial cell chemotaxis stimulated by bFGF or the placental angiogenic hormone proliferin (31, 32) . In contrast, VEGF-or S1P-induced HUVEC migration was reported to be independent of ERK (21, 33) . As shown in Fig. 7A, U0126 , a specific inhibitor of MAPK, had no effect on TRANCE-induced cell motility. The lack of inhibitory effect of U0126 indicates that the ERK activity is not required for HUVEC migration by TRANCE. Unlikely to inhibit the MAPK inhibitor U0126, the Src tyrosine kinase inhibitor PP1 significantly inhibited TRANCE-induced HUVEC chemotaxis, whereas it did not alter basal migration (Fig. 7B) , suggesting that Src kinases are closely involved in TRANCE-induced en- dothelial cell migration. This inhibitory effect of PP1 on cell migration is consistent with our finding that Src kinases are required for TRANCE-induced p125 FAK activation in HUVECs. Our data further showed that the stimulatory effect of TRANCE on HUVEC chemotaxis was significantly abrogated by the PLC inhibitor U73122 (Fig. 7C) , indicating the role of PLC in TRANCE-stimulated HUVEC migration. Moreover, TRANCE-induced HUVEC migration was blocked by the intracellular Ca 2ϩ chelator but not by the PKC inhibitor (Fig. 7D) . Theses results indicate that PLC-regulated intracellular Ca 2ϩ mobilization plays an important role in HUVEC migration by TRANCE.
DISCUSSION
In this report, we demonstrate that TRANCE has a novel function as an angiogenic factor. TRANCE stimulated angiogenesis in vivo by the mouse Matrigel plug assay and CAM assay. In the mouse Matrigel plug assay, the ability of TRANCE to promote neovessel formation was comparable with that of the well established angiogenic factor bFGF. In in vitro angiogenesis models, we have revealed that the stimulation of HUVECs with TRANCE leads to an increase in cell proliferation as well as chemotactic motility and strongly induces the formation of tube network. Our data also showed that the mechanism by which TRANCE induces angiogenesis is dissimilar to TNF␣, which requires VEGF expression for its angiogenic activity. The angiogenic activity of TRANCE appeared to be the result of its direct action on endothelial cells. Thus, we demonstrate here a novel biological action of TRANCE in vasculature formation in addition to the regulatory functions previously identified in immune responses and bone development (15, 34) .
The present study demonstrates the TRANCE signaling pathway in endothelial cells (Fig. 8) . We have delineated the expression and functionality of the cognate TRANCE receptor RANK in human endothelial cells. RANK expression in HUVECs and HMEC-1 was confirmed by RT-PCR, Western blot, and fluorescence-activated cell sorter analysis using fluorescein isothiocyanate-TRANCE ( Fig. 1 and data not shown) . As reported in osteoclasts and dendritic cells (16) , activation of the receptor downstream signaling mediators, such as ERKs, Src, and AKT, was observed in HUVECs. Interestingly, we recently found that VEGF pretreatment increased RANK expression on the surface of HUVECs and subsequently potentiated the effects of TRANCE on ERK activation and tube formation. 2 Therefore, these observations indicate that RANK is an active signaling receptor of TRANCE in endothelial cells.
Our data show that TRANCE induces activation of ERK1/2 and p125 FAK , which are closely linked to angiogenesis. Importantly, both Src and PLC are found to be the critical downstream molecules of RANK leading to these signaling events in human endothelial cells. In consistent with our data, the role of Src in TRANCE-induced signaling pathway was previously reported. Indeed, it has been demonstrated that a deficiency in Src blocks TRANCE-induced AKT activation in osteoclasts and dendritic cells in vitro and that the Src activity is required for TRANCE-mediated osteoclast survival (16, 35) . Additionally, we found that Src and PLC were required for TRANCE-induced HUVEC migration. The roles of these signaling molecules in angiogenesis are implicated in other systems. It has been shown that activation of Src is essential for VEGF-induced angiogenesis and that PLC is required for S1P-induced cell migration (36, 37) . Several lines of evidence also noted the significant role of Ca 2ϩ in endothelial cell migration (27, 37) . In particular, a recent study showed that VEGF increases intracellular Ca 2ϩ leading to the generation of nitric oxide (NO) by activation of endothelial NO synthase, and the resulting endothelial NO production is required for VEGF-induced angiogenesis including endothelial cell proliferation, migration, and network formation (27) . Our results indicate that TRANCEinduced endothelial cell motility requires increases in intracellular Ca 2ϩ . Therefore, our findings raise the possibility that NO production via the Src-PLC-Ca 2ϩ signaling pathway may be an essential step in TRANCE-induced angiogenesis. Alternatively, AKT can mediate endothelial cell survival and lead to increases in NO production via activation of endothelial NO synthase (38) . Since we observed that TRANCE activated AKT in HUVECs (data not shown), the AKT signaling pathway may in part contribute to the angiogenic processes triggered by TRANCE. These possibilities are under investigation.
New blood vessel formation is required for endochondral bone formation by serving as the conduit that allows a variety of cells essential for bone morphogenesis (endothelial cells, chondroclasts, and osteoblasts) to migrate into the growth plate. A recent study demonstrates that VEGF generated from hypertrophic chondrocytes in the epiphyseal growth plate couples hypertrophic cartilage remodeling, ossification, and angiogenesis during endochondral bone formation (19) . Since the angiogenic processes in vivo are regulated by coordinative action of various angiogenic factors in addition to VEGF, another factor generated from cells inside or in the close vicinity of cartilage seems to be involved in the progression of angiogenesis during bone formation. Therefore, our findings strongly suggest that TRANCE produced by osteoblasts may play a cooperative role with VEGF in the proper vascular formation during bone growth and remodeling. Angiogenesis is also an essential requirement for tumor growth and metastasis and is regulated by a complex network of factors that interact between stromal cells, endothelial cells, and neoplastic cells within solid tumor. Cytokines, such as IL-1␤, IL-6, IL-11, IL-17, and TNF␣, generated by tumor-associated macrophages, increase the expression of TRANCE with decrease of OPG expression in stromal cells (39) . This evidence suggests that TRANCE produced by stromal cells may be involved in the formation of microvessels in the tumor site. Furthermore, inflammatory cytokines TNF␣ and IL-1␣ elevate TRANCE expression in human microvascular endothelial cells (40) . These results together with our observation suggest that the timely generation of 
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matory cytokines may in part contribute to new vasculature formation in an inflammatory site. Thus, we propose that TRANCE can act as an important modulator of angiogenesis under physiological and pathological conditions.
